Biermann J, Melms JC, Amin ADipak, Wang Y, Caprio LA, Karz A, Tagore S, Barrera I, Ibarra-Arellano MA, Andreatta M et al..  2022.  Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.. Cell. 185(14):2591-2608.e30.

Lau CM, Adams NM, Geary CD, Weizman O-E, Rapp M, Pritykin Y, Leslie CS, Sun JC.  2018.  Epigenetic control of innate and adaptive immune memory.. Nat Immunol. 19(9):963-972.

Clemente-Casares X, Hosseinzadeh S, Barbu I, Dick SA, Macklin JA, Wang Y, Momen A, Kantores C, Aronoff L, Farno M et al..  2017.  A CD103 Conventional Dendritic Cell Surveillance System Prevents Development of Overt Heart Failure during Subclinical Viral Myocarditis.. Immunity. 47(5):974-989.e8.

Tian T, Jin MQiushuang, Dubin K, King SL, Hoetzenecker W, Murphy GF, Chen CAmy, Kupper TS, Fuhlbrigge RC.  2017.  IL-1R Type 1-Deficient Mice Demonstrate an Impaired Host Immune Response against Cutaneous Vaccinia Virus Infection.. J Immunol. 198(11):4341-4351.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L et al..  2017.  An immunogenic personal neoantigen vaccine for patients with melanoma.. Nature. 547(7662):217-221.

Levine AG, Mendoza A, Hemmers S, Moltedo B, Niec RE, Schizas M, Hoyos BE, Putintseva EV, Chaudhry A, Dikiy S et al..  2017.  Stability and function of regulatory T cells expressing the transcription factor T-bet.. Nature. 546(7658):421-425.

Zhen A, Rezek V, Youn C, Lam B, Chang N, Rick J, Carrillo M, Martin H, Kasparian S, Syed P et al..  2017.  Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.. J Clin Invest. 127(1):260-268.

Chinen T, Kannan AK, Levine AG, Fan X, Klein U, Zheng Y, Gasteiger G, Feng Y, Fontenot JD, Rudensky AY.  2016.  An essential role for the IL-2 receptor in T cell function.. Nat Immunol. 17(11):1322-1333.

Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D et al..  2016.  Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.. Cancer Immunol Res. 4(11):936-947.

Do MH, Li MO.  2016.  Metabolic control of asyMYCtric division.. Cell Res. 26(8):863-4.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A et al..  2016.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.. Genome Biol. 17(1):231.

Kim SG, Lowe EL, Dixit D, Youn CSeyeon, Kim IJ, Jung JB, Rovner R, Zack JA, Vatakis DN.  2015.  Cocaine-mediated impact on HIV infection in humanized BLT mice.. Sci Rep. 5:10010.

Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT et al..  2015.  Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.. Cancer Cell. 27(4):489-501.

Blachere NE, Orange DE, Santomasso BD, Doerner J, Foo PK, Herre M, Fak J, Monette S, Gantman EC, Frank MO et al..  2014.  T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation.. Eur J Immunol. 44(11):3240-51.

Diab A, Jenq RR, Rizzuto GA, Cohen AD, Huggins DW, Merghoub T, Engelhorn ME, Guevara-Patiño JA, Suh D, Hubbard-Lucey VM et al..  2013.  Enhanced responses to tumor immunization following total body irradiation are time-dependent.. PLoS One. 8(12):e82496.

Vatakis DN, Arumugam B, Kim SG, Bristol G, Yang O, Zack JA.  2013.  Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression.. Mol Ther. 21(5):1055-63.

Tian T, Dubin K, Jin Q, Qureshi A, King SL, Liu L, Jiang X, Murphy GF, Kupper TS, Fuhlbrigge RC.  2012.  Disruption of TNF-α/TNFR1 function in resident skin cells impairs host immune response against cutaneous vaccinia virus infection.. J Invest Dermatol. 132(5):1425-34.

Kitchen SG, Levin BR, Bristol G, Rezek V, Kim S, Aguilera-Sandoval C, Balamurugan A, Yang OO, Zack JA.  2012.  In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells.. PLoS Pathog. 8(4):e1002649.

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A et al..  2011.  Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.. Proc Natl Acad Sci U S A. 108(51):E1408-16.

Wei H-J, Wu ATH, Hsu C-H, Lin Y-P, Cheng W-F, Su C-H, Chiu W-T, Whang-Peng J, Douglas FL, Deng W-P.  2011.  The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine.. Mol Ther. 19(12):2249-57.

Roberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N, Dousmanis AG, Posner JB, Darnell RB.  2009.  Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.. J Clin Invest. 119(7):2042-51.

Martin DL, D Weatherly B, Laucella SA, Cabinian MA, Crim MT, Sullivan S, Heiges M, Craven SH, Rosenberg CS, Collins MH et al..  2006.  CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes.. PLoS Pathog. 2(8):e77.

Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L et al..  1999.  Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.. J Exp Med. 189(6):991-8.